RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

(NASDAQ: RDNT) RadNet, Inc. reported financial results for its third quarter of 2026, highlighting record quarterly Revenue and Adjusted EBITDA. Total Company Revenue for Q3 2026 was $638.3 million, representing a 22.1% increase over the prior year, and Adjusted EBITDA was $105.0 million, up 23.8%. The Adjusted EBITDA margin expanded by 23 basis points. These results were attributed to initiatives such as capacity creation at existing centers, new center openings, a shift toward advanced imaging, tuck-in acquisitions, improved commercial payor reimbursement, expansion of health system joint ventures, and 32.6% revenue growth in the Digital Health segment. Aggregate advanced imaging procedural volumes increased 19.9% year-over-year, and same-center advanced imaging procedural volumes increased 8.9%. The advanced imaging business mix rose from 28.2% in Q3 2025 to 30.6% in Q3 2026, an increase of 232 basis points. MRI volume increased 18.3%, CT volume increased 22.0%, and PET/CT volume increased 30.4% compared to Q3 2025. Overall imaging exam volume increased 10.8% year-over-year, and same-center overall volume increased 3.2%. Digital Health Revenue for Q3 2026 was $32.9 million, up $8.1 million or 32.6%, while Adjusted EBITDA for the segment was $3.0 million, down $0.4 million or -11.8%. Unadjusted Total Company Net Income for Q3 2026 was $4.2 million, compared to $5.4 million in Q3 2025. Fully diluted Net Income Per Share was $0.05, compared to $0.07 in Q3 2025, with 79.2 million diluted shares outstanding in Q3 2026. Noteworthy items impacting Q3 included $1.2 million in severance expense, $7.5 million gain on contribution of imaging centers into joint ventures, $0.6 million expense for leases on de novo facilities under construction, $5.4 million loss on equipment disposal, $7.3 million intangibles amortization for Digital Health, $5.6 million non-capitalized R&D expenses for DeepHealth Cloud OS and AI, $2.8 million in legal settlements, $2.7 million acquisition transaction costs, $8.3 million non-cash change in contingent consideration, and $2.1 million lease abandonment charges. Adjusted for these items, Total Company Adjusted Earnings for Q3 2026 was $23.8 million and diluted Adjusted Earnings Per Share was $0.30, compared to $18.8 million and $0.24, respectively, in Q3 2025. For the first nine months of 2026, Total Company Revenue was $1,836.6 million, up $344.1 million or 23.1%, and Adjusted EBITDA was $268.0 million, up $55.4 million or 26.1%. Digital Health Revenue for the nine months was $94.5 million, up $29.7 million or 45.8%, and Adjusted EBITDA was $6.8 million, down $3.7 million or -35.4%. Unadjusted Total Company Net Loss for the nine months was $21.8 million, compared to $18.1 million in the prior year. Fully diluted Net Loss Per Share for the nine months was $(0.28), compared to $(0.24) in 2025, with 77.6 million diluted shares outstanding. At the end of Q3 2026, RadNet had $750.6 million in cash and a Net Debt to Adjusted EBITDA leverage ratio of 1.66x. The company raised its 2026 Imaging Center guidance ranges: Total Net Revenue to $2,385 - $2,435 million, Adjusted EBITDA to $350 - $363 million, Capital Expenditures to $170 - $180 million, Cash Interest Expense to $48 - $53 million, and Free Cash Flow to $120 - $130 million. Digital Health segment guidance was maintained for Total Net Revenue at $135 - $145 million, Adjusted EBITDA before non-capitalized R&D at $11 - $13 million, Non-Capitalized R&D at $17 - $19 million, Capital Expenditures at $10 - $13 million, Free Cash Flow before non-capitalized R&D at $(1) - $3 million, and Free Cash Flow after non-capitalized R&D at $(17) - $(19) million. The company referenced the pending acquisition of ONRAD and noted strong inbound interest from joint venture partners and customers. Dr. Howard Berger is President and Chief Executive Officer, and Mark Stolper is Executive Vice President and Chief Financial Officer. A conference call to discuss results was scheduled for November 9, 2026.

RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges

(NASDAQ: RDNT) RadNet, Inc. reported Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025. Digital Health reportable segment revenue increased 56.5% to $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025, and Annual Recurring Revenue (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026. Total Company Adjusted EBITDA was a quarterly record of $99.7 million in the second quarter of 2026, up from $81.2 million in the second quarter of 2025, an increase of 22.7%. Adjusted Earnings were $23.2 million and Adjusted Earnings Per Share was $0.29 for the second quarter of 2026, compared to $25.7 million and $0.34, respectively, for the second quarter of 2025. Aggregate advanced imaging procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025. As of June 30, 2026, balance sheet cash was $726.3 million and Net Debt to Adjusted EBITDA Ratio was 1.8x. The company projects to implement DeepHealth’s breast ultrasound AI solution across RadNet’s breast imaging centers by year-end and anticipates both Revenue and cost savings contributions in the second half of this year from the roll-out.

RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%

(NASDAQ: RDNT) RadNet, Inc. announced that it has entered into Incremental Amendment No. 3 to its Third Amended and Restated First Lien Credit and Guaranty Agreement, securing an incremental term loan in the aggregate principal amount of $250.0 million. The 2026 Incremental Term Loan will mature on April 18, 2031, coinciding with the maturity date of the $958.7 million balance of the Existing Term Loan. Quarterly payments of principal on the Term Loan will be approximately $3.1 million, compared to approximately $2.4 million prior to the amendment. The interest rate on the Term Loan was reduced by 0.25% to either Term SOFR plus 2.00% or the alternate base rate plus 1.00%, and the interest rate on RadNet’s existing $282 million revolving credit facility was also reduced by 0.25%. RadNet has provided call protection to the term loan lenders participating in the repricing of the Existing Term Loan for a period of six months following the Third Amendment. The proceeds of the 2026 Incremental Term Loan are expected to be used to finance future acquisitions, organic expansion initiatives, health system partnerships, and for other general corporate purposes. As of March 31, 2026, RadNet had a $455 million cash balance and over 11,000 team members.

RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow

RadNet, Inc. (NASDAQ: RDNT) reported a 22.1% increase in Total Company Revenue to $575.6 million for the first quarter of 2026, up from $471.4 million in the first quarter of 2025. Adjusted EBITDA rose 36.3% to $63.3 million, while Annual Recurring Revenue for Digital Health nearly doubled to $96.9 million. The company revised its full-year 2026 Imaging Center guidance upwards for Revenue, Adjusted EBITDA, and Free Cash Flow, and reaffirmed all Digital Health guidance ranges. Notably, RadNet completed the acquisition of Gleamer SAS in France and announced a new joint venture with Trinity Health’s Saint Alphonsus Health System. These results and strategic moves are significant for investors as they demonstrate strong growth, operational momentum, and expansion in digital health and imaging services.